Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma
Adjuvant CIK cell immunotherapy after curative treatment significantly prolongs RFS in early-stage HCC patients. Further research regarding the broader applications of CIK cell immunotherapy in HCC is warranted.
Authors
- Sang Hoon Ahn (ORCID: https://orcid.org/0000-0002-3629-4624)
- Gi Hong Choi (ORCID: https://orcid.org/0000-0002-1593-3773)
- Jun Yong Park (ORCID: https://orcid.org/0000-0001-6324-2224)
- Do Young Kim (ORCID: https://orcid.org/0000-0002-8327-3439)
- Hyoung‐Il Kim (ORCID: https://orcid.org/0000-0002-6134-4523)
- Mi Na Kim (ORCID: https://orcid.org/0000-0002-1675-0688)
- Beom Kyung Kim (ORCID: https://orcid.org/0000-0002-5363-2496)
- Seung Up Kim (ORCID: https://orcid.org/0000-0002-9658-8050)
- Jae Seung Lee (ORCID: https://orcid.org/0000-0002-2371-0967)
- Hye Won Lee (ORCID: https://orcid.org/0000-0002-3552-3560)
- Eun Min Kim
Institutions
- Yonsei University (KR)
- Severance Hospital (KR)
Publication Details
- Journal
- Cancers
- Published
- 2025-02-07
- DOI
- https://doi.org/10.3390/cancers17040566
- Citations
- 4
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 3.19
Funders
- National Research Foundation
- Yonsei University
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea
- Yonsei University College of Medicine